Brief: Jasper Therapeutics Announces Positive Follow-Up Clinical Data From Investigator-Sponsored Study Of Briquilimab Conditioning In Sickle Cell Disease Patients
16/02/2023 23:03
Feb 16 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES POSITIVE FOLLOW-UP CLINICAL
DATA
FROM INVESTIGATOR-SPONSORED STUDY OF BRIQUILIMAB CONDITIONING IN
SICKLE CELL DISEASE PATIENTS
* JASPER THERAPEUTICS INC - FIRST TWO SICKLE CELL DISEASE
PARTICIPANTS HAVE ACHIEVED 100% DONOR MYELOID CHIMERISM THROUGH
100 DAYS FOLLOW-UP
* JASPER THERAPEUTICS INC - THIRD SICKLE CELL DISEASE
PARTICIPANT
HAS NOW ACHIEVED 100% DONOR MYELOID CHIMERISM THROUGH 30 DAYS
FOLLOW-UP
* JASPER THERAPEUTICS INC - ALL THREE PARTICIPANTS HAVE
INCREASED
THEIR HEMOGLOBIN AT LAST FOLLOW-UP RELATIVE TO BASELINE
Source text for Eikon: ID:nGNXb46fq8
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma